CD8A and hepatocellular carcinoma: In an additional control, we found that aldometanib did not significantly enhance the tumoricidal effects of previously activated CD8+ T cells toward Hepa1-6 cells when co-cultured in vitro (Supplementary information, Fig. S11s), reinforcing the conclusion that the suppression of HCC by aldometanib relies on its ability to promote the infiltration and activation of CD8+ T cells in vivo.